Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when APUS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal NYSE notice of non-compliance with listing standards due to late 10-K filing.
Apimeds receives NYSE delisting notice for late 2025 annual report; stock halted since April 2
Filed April 22, 2026 · Period ending April 17, 2026 · ~1 min read
Key Changes
-
high
NYSE notified company on April 17 of non-compliance due to failure to file 2025 annual report on time. Company has 6 months to file the 10-K or face delisting, with possible 6-month extension.
Item 3.01 verify on EDGAR → -
high
Stock trading remains halted since April 2, 2026. When trading resumes, ticker will carry '.LF' suffix marking the company as a late filer until compliance is restored.
Item 3.01 verify on EDGAR → -
high
Company cited ongoing financial statement preparation and additional auditor time needed as reasons for delay. Expects to file by April 30, 2026, but provides no assurance.
Item 3.01 verify on EDGAR →
Summary
Apimeds Pharmaceuticals disclosed it received a formal deficiency notice from the NYSE on April 17 for failing to file its 2025 annual report on time. The company has six months to cure the deficiency by filing the overdue 10-K, with a possible additional six-month extension at the exchange's discretion.
The stock has been halted from trading since April 2 and will carry a '.LF' late filer designation when it resumes. The company attributed the delay to ongoing preparation of fourth quarter and full-year 2025 financial statements and additional time required for its auditor to complete audit procedures. While Apimeds expects to file by April 30, 2026, it provided no assurance it will meet that target.
Retail investors should monitor whether the company files its 10-K by the April 30 target date. Missing that deadline or requiring the full six-month cure period could signal deeper operational or financial issues beyond routine audit delays. The trading halt prevents investors from exiting positions, amplifying risk until normal trading resumes.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 17, 2026, Apimeds Pharmaceuticals US, Inc. (the “Company”) received a notice from the NYSE Regulation staff of the New York Stock Exchange (“NYSE”) indicating that the Company is not in compliance with NYSE’s continued listing requirements under the timely filing criteria outlined in Section 1007 of the NYSE American Listed Company Manual as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”).
The company failed to file its 2025 annual report on time and received a formal deficiency notice from the NYSE. The company has six months from April 17, 2026 to file the 10-K and regain compliance, with a possible additional six-month extension at NYSE's discretion. The stock will continue trading with a ".LF" designation indicating late filer status.
Added in current filing · verify on EDGAR →
The April 2, 2026, trading halt on the Company’s common stock remains in effect.
The company's stock has been halted from trading since April 2, 2026, and that halt remains in place despite the stock continuing to be listed on NYSE American.
Added in current filing · verify on EDGAR →
The Company’s common stock will continue to be listed on the NYSE American under the ticker symbol “APUS” while it attempts to regain compliance with the listing standard noted, but will have an added designation of “.LF” to signify the Company’s late filing status, which will remain in place until the Company regains compliance with the applicable listing standard.
The stock will trade with a ".LF" suffix added to its ticker symbol to publicly identify it as a late filer until the 10-K is filed and compliance is restored.
Event · Item 9.01 — Financial Statements and Exhibits
Apimeds filed an 8-K attaching a press release dated April 22, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release dated April 22, 2026.
The 8-K references an attached press release dated April 22, 2026 (Exhibit 99.1), but the filing body does not disclose the content or subject matter of that release. Without the exhibit text, the nature and materiality of the disclosed event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify